106IN - Lung Cancer Asia Study Group East

Date 29 September 2012
Event ESMO Congress 2012
Session ESMO-CSCO Joint symposium: Building the clinical trials of the future
Topics Bioethics, Legal, and Economic Issues
Lung and other Thoracic Tumours
Presenter Yi-Long Wu
Authors Y. Wu
  • Guangdong Lung Cancer Institute, Guangdong General Hospital (GGH) & Guangdong Academy of Medical Sciences, 510080 - Guangzhou/CN

Abstract

Over the past 10 years, there have been significant advances in clinical trials and translation research on lung cancer in China. The significant event was the discovery of EGFR mutation in 2004. The first international clinical trial involved in Chinese investigators was INTERESTIN that compared gefitinib with docetacel in second lint treatment for advanced NSCLC. The most important international trial in China was IPASS. Sixteen centers from China contributed 31% cases (372/1217). On the above basis the Chinese Thoracic Oncology Group (CTONG) was found in 2007. CTONG's mission is to design and develop multicenter clinical trials and provide a high level of evidence for clinical practice. Now the CTONG has 23 active centers. There are more 10 thousand new lung cancer cases per year in CTONG centers.

As the first national cooperative group CTONG has led some important trials that had changed clinical practice. CTONG 0802 (OPTIMAL) established the role of erlotinib in first line setting for patients with advanced NSCLC and EGFR mutation. Its results have helped to register erlotinib as first-line therapy in China and Europe. The CTONG 0804 (INFORM) is the first maintenance study on gefitinib, and published on Lancet Oncology. The table lists the ongoing CTONG studies that focus on biomarker driven clinical trials.

CTONG trials focusing on biomarkers.

Study number NCT number Title Status
CTONG 0806 00891579 Pemetrexed versus Gefitinib in Patients with EGFR wild type and metastatic NSCLC who failure to platinum-based chemotherapy Recruiting
CTONG 0901 01024413 Erlotinib versus Gefitinib in Advanced NSCLC with Exon 19 or 21 Mutations Recruiting
CTONG 1002 01236716 Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of the Lung Recruiting
CTONG 1103 01407822 Erlotinib versus chemotherapy as neoadjuvants in IIIA-N2 NSCLC with EGFR mutations in Exon 19 or 21 (EMERGING) Recruiting
CTONG 1104 01405079 Gefitinib versus Vinorelbine/Platinum as adjuvant treatments in Stage II-IIIA (N1-N2) NSCLC with EGFR Mutations (ADJUVANT) Recruiting

Chinese investigators are also very active in molecular biomarker researches. The tumor bank of lung cancer with more 4000 sample was set up. Extensive translational works on EGFR mutations including EGFR heterogeneity and mutation profile on lung adenocarcinoma were investigated. More high-quality translational research is expected in the future.

Disclosure

The author has declared no conflicts of interest.